Home » Stocks » Moleculin Biotech

Moleculin Biotech, Inc. (MBRX)

Stock Price: $1.08 USD -0.03 (-2.70%)
Updated Aug 7, 2020 4:00 PM EDT - Market closed
After-hours: $1.09 +0.01 (0.93%) Aug 7, 7:45 PM

Stock Price Chart

Key Info

Market Cap 65.24M
Revenue (ttm) n/a
Net Income (ttm) -10.37M
Shares Out 60.40M
EPS (ttm) -0.23
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 7, 2020
Last Price $1.08
Previous Close $1.11
Change ($) -0.03
Change (%) -2.70%
Day's Open 1.08
Day's Range 1.07 - 1.09
Day's Volume 1,038,000
52-Week Range 0.32 - 1.97

More Stats

Market Cap 65.24M
Enterprise Value 53.83M
Earnings Date (est) Aug 17, 2020
Ex-Dividend Date n/a
Shares Outstanding 60.40M
Float 45.93M
EPS (basic) -0.22
EPS (diluted) -0.23
FCF / Share -0.36
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 3.69M
Short Ratio 0.73
Short % of Float 6.10%
Beta 2.44
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 4.38
Revenue n/a
Operating Income -18.02M
Net Income -10.37M
Free Cash Flow -17.73M
Net Cash 11.40M
Net Cash / Share 0.19
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -48.15%
ROE -69.21%
ROIC 289.70%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (3)

Buy 3
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(208.33% upside)
Current: $1.08
Target: 3.33
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-17.52-15.03-8.65-3.88-0.47-1.65
Net Income-13.21-11.88-9.81-3.93-0.37-1.81
Shares Outstanding40.7225.9018.579.836.61-
Earnings Per Share-0.32-0.46-0.53-0.40--
Operating Cash Flow-17.20-12.20-7.32-3.77-0.72-1.35
Capital Expenditures-0.05-0.42-0.03-0.02--
Free Cash Flow-17.25-12.62-7.35-3.79-0.72-1.35
Cash & Equivalents10.747.137.715.010.030.52
Total Debt0.28--0.300.451.63
Net Cash / Debt10.467.137.714.71-0.42-1.10
Book Value15.5714.2717.1214.96-0.74-2.47
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Moleculin Biotech, Inc.
Country United States
Employees 11
CEO Walter V. Klemp

Stock Information

Ticker Symbol MBRX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: MBRX
IPO Date June 2, 2016


Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of oncology drug candidates. Its lead drug candidate is Annamycin for the treatment of relapsed or refractory acute myeloid leukemia (AML) and lung-localized tumors. The company's flagship immune/transcription modulator is WP1066, a STAT3 inhibitor, which is in Phase I clinical trial for the treatment of brain tumor, as well as to treat pancreatic cancer, AML, and glioblastoma. It also develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma in Poland; and WP1732, an analog of WP1066 for the treatment of AML, pancreatic, and other cancers. The company's lead metabolism/glycosylation inhibitor compound is WP1122, a prodrug of 2-deoxyglucose to treat brain tumors and pancreatic cancer. In addition, it develops WP1234 for the treatment of pancreatic cancer. Further, the company engages in the preclinical development of other drug candidates, including other immune/transcription modulators and metabolism/glycosylation inhibitors. It has an agreement with the University of Iowa Pharmaceuticals for the development of a formulation for WP1732; collaboration with Dermin Sp. Zoo for the development of WP1220; collaboration with M.D. Anderson Cancer Center for the development of WP1732 and WP1066; and material transfer agreement with the University of Texas Medical Branch at Galveston, d/b/a UTMB Health. Moleculin Biotech, Inc. was founded in 2015 and is headquartered in Houston, Texas.